



PATENT
Customer No. 22,852
Attorney Docket No. 08505.0020-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
Jenkins, Peter James et al.)	Group Art Unit: 1623
Application No.: 10/776,188)	Examiner: E. Peselev
Filed: February 12, 2004)	
For: PREPARATION AND DIABETIC USE OF GIBBERELLINS)	Confirmation No.: 3089

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.
§ 1.97(d)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicants bring to the attention of the Examiner the document on the attached listing. This Supplemental Information Disclosure Statement is being filed after a Final Action and is accompanied by a fee of \$180.00 as specified under § 1.17(p) and a certification as specified under § 1.97(e)(2). Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notation on the attached form.

Based on reasonable inquiry, no document listed in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and no document listed in this Supplemental

07/03/2006 EAREGAY1 00000077 10776188

02 FC:1806

180.00 OF

Application No. 10/776,188
Attorney Docket No. 08505.0020

Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of this Supplemental Information Disclosure Statement.

A copy of the listed non-patent literature document is enclosed.

Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notation on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitute "prior art." If the Examiner applies this document as prior art against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such a document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claims of the present application.

Application No. 10/776,188
Attorney Docket No. 08505.0020

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,


Australian Biomedical Company Pty, Ltd.

Dated: 16th June 2006

By: _____

Name: WEN YANG WU

Title: DIRECTOR



JUN-14-2006 15:03 From: FINNEGHN HENDERSON 6174521666

To: Phillips Urmonde P.P.6/11

IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	
				Filing Date	
				First Named Inventor	
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	00505.0020-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		MacRury et al., "Changes in Phagocytic Function With Glycaemic Control in Diabetic Patients," J. Clin. Pathol. 42:1143-1147 (1989).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.